navelbine 10 mg/ml koncentrátum oldatos infúzióhoz
pierre fabre médicament - vinorelbine -
navelbine 20 mg lágy kapszula
pierre fabre médicament - vinorelbine -
navelbine 30 mg lágy kapszula
pierre fabre médicament - vinorelbine -
navelbine 80 mg lágy kapszula
pierre fabre médicament - vinorelbine -
vinorelbin alvogen 20 mg lágy kapszula
zentiva, k.s. (csehország) - vinorelbine -
vinorelbin alvogen 30 mg lágy kapszula
zentiva, k.s. (csehország) - vinorelbine -
zoledronsav ranbaxy 4 mg/5 ml koncentrátum oldatos infúzióhoz
ranbaxy uk ltd. - zoledronsav -
navelbin 10 mg/1 ml injekció
pierre fabre médicament -
navelbin 50 mg/5 ml injekció
pierre fabre médicament - vinorelbine -
imfinzi
astrazeneca ab - durvalumab - karcinóma, nem kissejtes tüdő - daganatellenes szerek - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).